

A microscopic view of blood cells and fibrin clots. Red blood cells are shown as large, biconcave discs in shades of red. Yellow and orange fibrin strands are interwoven, forming a mesh that traps some of the red blood cells. A few blue, irregularly shaped cells are also visible.

Coagulation Conundrums

Allan Platt, PA-C, MMSc
Faculty, Physician Assistant Program
Emory University School of Medicine
Atlanta, GA
aplatt@emory.edu
www.EmoryPA.org


Disclosure

- I have nothing to disclose except
 - I do work for food
 - I promote giving blood
 - I did write chapter 4 in



BBQ ribs are best!

Paid a set fee
for Hematology
review - no
royalties



Give life!



Objectives

At the end of this session, participants should be able to:

- Recognize common laboratory patterns for common bleeding disorders seen in primary care
- Diagnose common bleeding and clotting disorders
- Formulate a treatment plan or referral for common bleeding and clotting disorders

Lab Report

Most common labs

- CBC
 - WBC Diff
 - RBC morphology
 - Retic count
- Complete Metabolic Profile
- UA with micro
- Coagulation
 - PT (INR)
 - aPTT
 - d-Dimer
 - PFA

APERTURE LABORATORIES WE DO WHAT WE MUST, BECAUSE WE CAN		PATIENT INFORMATION:		Normal	
SPECIMEN INFORMATION: SPECIMEN: P121982AQW REQUESTION: 1973200- LAB REFERENCE #: H9000		NAME: John Smith Age: 40		ORDERING PHYSICIAN: C. Johnson	
		GENDER: Male		CLIENT INFORMATION:	
		ID: 1.071.09		EMORY PA CLINICAL OSCE	
		PHONE:		1462 CLIFTON RD NE ATLANTA, GA 30322	
COLLECTED: 12/17/12 RECEIVED: 12/17/12 REPORTED: 12/17/12					
CBC (includes Diff/Plt)		Urinalysis (u/A)			
White blood cell count	9.0	3.8-10.8 Thousand/ μ L	color	Yellow	
Red Blood Cell Count	4.5	F 4.2 - 5.4 M 4.6 - 6 million/ mm^3	Appearance	clear	
Hemoglobin	14	F 11-16 M 13.5 - 18g/dL	Specific Gravity	1.024	
Hematocrit	42	F 35-45 M 40-54 %	pH	6	
MCV	92.2	80.0-100.0 fl	Protein	Negative	
MCH	31.6	27.0-33.0 pg	Glucose	Negative	
MCHC	34.3	32.0-36.0 g/dL	Ketones	Negative	
RDW	13.5	11.0-15.0 %	Bilirubin	Negative	
Platelet Count	284	140-450 Thousand/ μ L	Blood	Negative	
Neutrophils	67	40-76%	Urobilinogen	0.2	
Bands	4	0-5%	Nitrite	Negative	
Lymphocytes	25	24-44%	Leukocyte Esterase	Negative	
Monocytes	3	3-7%	Microscopic		
Eosinophils	1	1-3%	WBCs/hpf	0	
Basophils	0.2	0-1%	RBC/hpf	0	
Other			Epithelial Cells/hpf	0	
Corrected Retic	2	2	Bacteria	0	
Metabolic Profile					
Total calcium	7.2	9 - 11 mg/dL			
BUN	16	6 - 20 mg/dL			
Creat	0.8	0.5 - 1.0 mg/dL			
T.Bili	1.0	0.3 - 1.2 mg/dL			
D. Bili	0.2	0 - 0.2 mg/dL			
U. Bili	0.9	0.2 - 0.8 mg/dL			
Alk Phos	44	32 - 103 IU/L			
ALT	20	10 - 30 U/L			
AST	9	8 - 46 U/L			
Total Protein	7.5	6-8 g/dL			
Albumin	3.5	3.4-4.8 g/dL			
LDH	75	50 - 150 U/L			
Sodium NA	140	136-145 mmol/L			
Potassium K	4.0	3.6-5.1 mmol/L			
Chloride CL	100	99-111 mmol/L			
Bicarb CO2	24	22-32 mmol/L			
Glucose	100	70-110 mg/dL			
		Coag			
		aPTT	30.0	23.3 - 36.6 sec	
		PT	10.2	9.1 - 13.2 Sec	
		PT INR	1	0.82 - 1.18	
		D-Dimer	0.25	0.2 - .44 FEU	
		PFA	120	CEPI <164 s; CADP <116 s	

Lab - CBC

- Cost \$30
- WBC count –infection defense
- Platelet count – clot ability
- Red Cells – O₂, CO₂, CO, NO gas transport, Buffer
 - Hb – Hemoglobin
 - Hct = % red cells/plasma
 - MCV = size of RBCs
 - MCH = Hb inside = Redness
 - RDW – red cell distribution width – higher = cells of different sizes

Cost <https://www.health-tests-direct.com/what-tests-are-available>

APERTURE LABORATORIES WE DO WHAT WE MUST, BECAUSE WE CAN.		PATIENT INFORMATION:		Normal	
SPECIMEN INFORMATION: SPECIMEN: P121982AQW REQUISITION: 1973200- LAB REFERENCE #: H9000		NAME: John Smith Age: 40		ORDERING PHYSICIAN: C. Johnson	
		GENDER: Male		CLIENT INFORMATION:	
		ID: 1.071.09		EMDRY PA CLINICAL OSCE	
		PHONE:		1462 CLIFTON RD NE ATLANTA, GA 30322	
COLLECTED: 12/17/12 RECEIVED: 12/17/12 REPORTED: 12/17/12					
CBC (includes Diff/Plt)			Urinalysis (u/A)		
White blood cell count	9.0	3.8-10.8 Thousand/ μ l	color		Yellow
Red Blood Cell Count	4.8	F 4.2 - 5.4 M 4.6 - 6 million/ mm^3	Appearance		clear
Hemoglobin	14	F 11-16 M 13.5 - 18g/dl	Specific Gravity		1.02
Hematocrit	42	F 35-45 M 40-54 %	pH		6
MCV	92.3	80.0-100.0 fl	Protein		Negative
MCH	31.6	27.0-33.0 pg	Glucose		Negative
MCHC	34.3	32.0-36.0 g/dl	Ketones		Negative
RDW	13.9	11.0-15.0 %	Bilirubin		Negative
Platelet Count	284	140-450 Thousand/ μ l	Blood		Negative
Neutrophils	67	40-76%	Urobilinogen		0.2
Bands	4	0-5%	Nitrite		Negative
Lymphocytes	25	24-44%	Leukocyte Esterase		Negative
Monocytes	3	3-7%	Mikroskopis		
Eosinophils	2	1-3%	WBCs/hpf		0
Basophils	0.2	0-1%	RBC/hpf		0
Other			Epithelial Cells/hpf		0
Corrected Reti	2	2	Bacteria		0
Metabolic Profile					
Total Calcium	7.2	9 - 11 mg/dL			
BUN	16	6 - 20 mg/dL			
Creat	0.8	0.5 - 1.0 mg/dL			
T.Bili	1.0	0.3 - 1.2 mg/dL			
D. Bili	0.3	0 - 0.2 mg/dL			
U. Bili	0.5	0.2 - 0.8 mg/dL			
Alk Phos	44	32 - 103 IU/L			
ALT	20	10 - 30 U/L			
AST	9	8 - 46 U/L			
Total Protein	7.5	6-8 g/dL			
Albumin	3.5	3.4-4.8 g/dL			
LDH	75	50 - 150 U/L			
Sodium NA	140	136-145 mmol/L			
Potassium K	4.0	3.6-5.1 mmol/L			
Chloride CL	100	99-111 mmol/L			
Bicarb CO ₂	24	22-32 mmol/L			
Glucose	100	70-110 mg/dL			
			Coag		
			APTT	30.0	23.3 - 36.6 sec
			PT	10.3	9.1 - 13.2 Sec
			PT INR	1	0.82 - 1.18
			D-Dimer	0.25	0.2 - .44 FEU
			PFA	120	CEPI <164 s; CADP <116 s

Lab – CBC Diff and Retic

- Do diff when WBC is high or low, chemo/drug monitoring
 - Bands = early Neutrophils
 - Neutrophils – Bacteria
 - Lymphs – (B, T, NK)Viral
 - Mono – TB, HIV, Mono
 - Eos – Allergy, parasites
 - Baso – Mast cell, allergy
- Retic count – when suspect anemia or monitor therapy. Must be corrected

APERTURE LABORATORIES WE DO WHAT WE MUST, BECAUSE WE CAN.		PATIENT INFORMATION:		Normal	
SPECIMEN INFORMATION:		NAME: John Smith Age: 40		ORDERING PHYSICIAN: C. Johnson	
SPECIMEN: P121982AQW		GENDER: Male		CLIENT INFORMATION:	
REQUESTION: 1973200-		ID: 1.071.09		EMORY PA CLINICAL OSCE	
LAB REFERENCE #: H9000		PHONE:		1462 CLIFTON RD NE	
COLLECTED: 12/17/12				ATLANTA, GA 30322	
RECEIVED: 12/17/12					
REPORTED: 12/17/12					
CBC (includes Diff/Pit)			Urinalysis (u/a)		
White blood cell count	9.0	3.8-10.8 Thousand/uL	color		Yellow
Red Blood Cell Count	4.6	F 4.2 - 5.4 M 4.6 - 6 million/mm ³	Appearance		clear
Hemoglobin	14	F 11-16 M 13.5 - 18g/dL	Specific Gravity		1.024
Hematocrit	42	F 35-45 M 40-54 %	pH		6
MCV	92.4	80.0-100.0 fl	Protein		Negative
MCH	31.6	27.0-33.0 pg	Glucose		Negative
MCHC	34.3	32.0-36.0 g/dL	Ketones		Negative
RDW	13.9	11.0-15.0 %	Bilirubin		Negative
Platelet Count	284	140-450 Thousand /uL	Blood		Negative
Neutrophils	67	40 -76%	Urobilinogen		0.2
Bands	4	0 - 5%	Nitrite		Negative
Lymphocytes	25	24 -44%	Leukocyte Esterase		Negative
Monocytes	3	3-7%	Microscopic		
Eosinophils	1	1-3%	WBCs/hpf		0
Basophils	0.2	0-1%	RBC/hpf		0
Other			Epithelial Cells/hpf		0
Corrected Retic	2	2	Bacteria		0
Metabolic Profile			Coag		
Total Calcium	7.2	9 - 11 mg/dL	aPTT	30.0	23.3 - 36.6 sec
BUN	16	6 - 20 mg/dL	PT	10.2	9.1 - 13.2 Sec
Creat	0.8	0.5 - 1.0 mg/dL	PT INR	1	0.82 - 1.18
T.Bili	1.0	0.3 - 1.2 mg/dL	D-Dimer	0.25	0.2 - .44 FEU
D.Bili	0.2	0 - 0.2 mg/dL	PFA	120	CEPI <164 s; GADP <116 s
I.Bili	0.9	0.2 - 0.8 mg/dL			
Alk Phos	44	32 - 103 IU/L			
ALT	20	10 - 30 U/L			
AST	9	8 - 46 U/L			
Total Protein	7.5	6 - 8 g/dL			
Albumin	3.5	3.4 - 4.8 g/dL			
LDH	75	50 - 150 U/L			
Sodium NA	140	136 - 145 mmol/L			
Potassium K	4.0	3.6 - 5.1 mmol/L			
Chloride CL	100	99 - 111 mmol/L			
Bicarb CO2	24	22 - 32 mmol/L			
Glucose	100	70 - 110 mg/dL			



CBC Patterns

- Pancytopenia – Marrow failure
- Thrombocytopenia – Liver/ Marrow/ Autoimmune/Infection
- Leukocytosis – Infection or leukemias

Lab -CMP Metabolic

Cost \$30 for CMP
Electrolytes

- Sodium (Na⁺) – maintains osmotic pressure, acid/base, nerve impulse transmission
- Chloride (Cl⁻) – acid/base and water balance
- Potassium (K⁺) – nerve conduction, muscle function, acid/base, osmotic pressure
- Calcium (Ca²⁺) - muscle, nerve, cardiac function, clotting
- Bicarb (CO₂) – Renal acid buffer to maintain pH
- Other
 - Glucose (Glu)
 - Blood Urea Nitrogen (BUN)
 - Creatinine (Creat)
 - Albumin (Alb)
 - Bilirubin (T Bili or D Bili)
 - Aspartate transaminase / aminotransferase (AST)
 - Alanine transaminase / aminotransferase (ALT)
 - Alkaline Phosphatase (Alk Phos)
 - Creatine phosphokinase (CPK)
 - Lactate dehydrogenase (LDH)
 - Total Protein (Prot)
 - Uric Acid (Uric)

APERTURE LABORATORIES WE DO WHAT WE MUST, BECAUSE WE CAN		PATIENT INFORMATION:		Normal	
SPECIMEN INFORMATION: SPECIMEN: P121982AQW REQUESTION: 1973200- LAB REFERENCE #: H9000		NAME: John Smith Age: 40		ORDERING PHYSICIAN: C. Johnson	
		GENDER: Male		CLIENT INFORMATION: EMORY PA CLINICAL OSCE 1462 CLIFTON RD NE ATLANTA, GA 30322	
ID: 1.071.09		PHONE:			
COLLECTED: 12/17/12 RECEIVED: 12/17/12 REPORTED: 12/17/12					
CBC (includes Diff/Plt)			Urinalysis (u/A)		
White blood cell count	9.0	3.8-10.8 Thousand/ μ L	color	Yellow	
Red Blood Cell Count	4.5	F 4.2 - 5.4 M 4.6 - 6 million/mm ³	Appearance	clear	
Hemoglobin	14	F 11-16 M 13.5 - 18g/dL	Specific Gravity	1.024	
Hematocrit	42	F 35-45 M 40-54 %	pH	6	
MCV	92.2	80.0-100.0 fl	Protein	Negative	
MCH	31.6	27.0-33.0 pg	Glucose	Negative	
MCHC	34.3	32.0-36.0 g/dL	Ketones	Negative	
RDW	13.5	11.0-15.0 %	Bilirubin	Negative	
Platelet Count	284	140-450 Thousand / μ L	Blood	Negative	
Neutrophils	67	40-76%	Urobilinogen	0.2	
Bands	4	0-5%	Nitrite	Negative	
Lymphocytes	25	24-44%	Leukocyte Esterase	Negative	
Monocytes	3	3-7%	Microscopic		
Eosinophils	1	1-3%	WBCs/hpf	0	
Basophils	0.2	0-1%	RBC/hpf	0	
Other			Epithelial Cells/hpf	0	
Corrected Retic	2	2	Bacteria	0	
Metabolic Profile					
Total calcium	7.2	9 - 11 mg/dL	Coag		
BUN	16	6 - 20 mg/dL	aPTT	30.0	23.3 - 36.6 sec
Creat	0.8	0.5 - 1.0 mg/dL	PT	10.2	9.1 - 13.2 Sec
T.Bili	1.0	0.3 - 1.2 mg/dL	PT INR	1	0.82 - 1.18
D. Bili	0.2	0 - 0.2 mg/dL	D-Dimer	0.25	0.2 - .44 FEU
U. Bili	0.9	0.2 - 0.8 mg/dL	PFA	120	CEPI <164 s; CADP <116 s
Alk Phos	44	32 - 103 IU/L			
ALT	20	10 - 30 U/L			
AST	9	8 - 46 U/L			
Total Protein	7.5	6-8 g/dL			
Albumin	3.5	3.4-4.8 g/dL			
LDH	75	50 - 150 U/L			
Sodium NA	140	136-145 mmol/L			
Potassium K	4.0	3.6-5.1 mmol/L			
Chloride CL	100	99-111 mmol/L			
Bicarb CO ₂	24	22-32 mmol/L			
Glucose	100	70-110 mg/dL			




CMP Patterns

- Renal disease – BUN/Creat/Albumin
- Liver Disease – AST/ALT/Alk Phos/
Albumin/Total Protein/Direct Bili
- Hemolysis – LDH/ Indirect Bili

Lab - Urine

Cost - \$35

- Specific Gravity (1.005-1.030) – how concentrated?
- pH (4.6-8) – acid/base balance
- Blood (-) – infection? trauma? MP? Other?
- Protein (-) – renal pathology? DM? due to blood in urine?
- Leukocytes/Leukocyte Esterase (-) – infection?
- Nitrite (-) – bacterial infection?
- Albumin (-) – renal pathology? DM? due to blood in urine?
- Glucose (-) – DM? renal pathology?
- Ketones (-) – Diabetic Ketoacidosis? Diet?
- Bilirubin (-) – Liver or biliary tract damage? Hemolysis?
- Urobilinogen + unobstructed bile ducts
- RBCs – stones, CA, bleed
- WBC – infection
- Casts – Kidney origin



APERTURE LABORATORIES
WE DO WHAT WE MUST, BECAUSE WE CAN.

PATIENT INFORMATION:
 NAME: John Smith Age: 40
 GENDER: Male
 ID: 1.071.09
 PHONE:

Normal

ORDERING PHYSICIAN: C. Johnson
 CLIENT INFORMATION:
 EMORY PA CLINICAL OSCE
 1462 CLIFTON RD NE
 ATLANTA, GA 30322

SPECIMEN INFORMATION:
 SPECIMEN: P121982AQW
 REQUISITION: 1973200-
 LAB REFERENCE #: H9000

COLLECTED: 12/17/12
 RECEIVED: 12/17/12
 REPORTED: 12/17/12

CBC (includes Diff/Plt)		
White blood cell count	9.0	3.8-10.8 Thousand/ μ L
Red Blood Cell Count	4.8	F 4.2 - 5.4 M 4.6 - 6 million/mm ³
Hemoglobin	14	F 11-16 M 13.5 - 18g/dL
Hematocrit	42	F 35-45 M 40-54 %
MCV	92.2	80.0-100.0 fL
MCH	31.6	27.0-33.0 pg
MCHC	34.3	32.0-36.0 g/dL
RDW	13.9	11.0-15.0 %
Platelet Count	284	140-450 Thousand / μ L
Neutrophils	67	40 - 76%
Bands	4	0 - 5%
Lymphocytes	25	24 - 44%
Monocytes	3	3-7%
Eosinophils	1	1-3%
Basophils	0.2	0-1%
Other		
Corrected Retic	2	2


Urinalysis (u/A)		
color		Yellow
Appearance		clear
Specific Gravity		1.024
pH		6
Protein		Negative
Glucose		Negative
Ketones		Negative
Bilirubin		Negative
Blood		Negative
Urobilinogen		0.2
Nitrite		Negative
Leukocyte Esterase		Negative
Microscopic		
WBCs/hpf		0
RBC/hpf		0
Epithelial cells/hpf		0
Bacteria		0

Metabolic Profile		
Total Calcium	7.2	9 - 11 mg/dL
BUN	16	6 - 20 mg/dL
Creat	0.8	0.5 - 1.0 mg/dL
T.Bil	1.0	0.3 - 1.2 mg/dL
D. Bil	0.2	0 - 0.2 mg/dL
I. Bil	0.9	0.2 - 0.8 mg/dL
Alk. Phos	44	32 - 103 IU/L
ALT	20	10 - 30 U/L
AST	9	8 - 46 U/L
Total Protein	7.5	6-8 g/dL
Albumin	3.5	3.4 - 4.8 g/dL
LDH	75	50 - 150 U/L
Sodium NA	140	136-145 mmol/L
Potassium K	4.0	3.6-5.1 mmol/L
Chloride CL	100	99-111 mmol/L
Bicarb CO2	24	22-32 mmol/L
Glucose	100	70-110 mg/dL

Coag		
aPTT	30.0	23.3 - 36.6 sec
PT	10.2	9.1 - 13.2 Sec
PT/INR	1	0.82 - 1.18
D-Dimer	0.25	0.2 - .44 FEU
PFA	120	CEPI <164 s; CADP <116 s

Lab - Coag

- PT /aPTT \$41
- D-Dimer/PFA \$30
- PT= Prothrombin Time = INR = extrinsic vitamin K clotting system (Coumadin)
- aPTT= activated Partial Thromboplastin Time = Intrinsic clotting system (Heparin)
- D-Dimer = Clot breakdown < or =250 ng/mL D-Dimer Units (DDU)
- < or =0.5 mcg/mL Fibrinogen Equivalent Units (FEU)
- PFA = Platelet Function Analysis = Platelet functioning



APERTURE LABORATORIES
WE DO WHAT WE MUST, BECAUSE WE CAN.

PATIENT INFORMATION: NAME: John Smith Age: 40 GENDER: Male ID: 1.071.09 PHONE:

ORDERING PHYSICIAN: C. Johnson CLIENT INFORMATION: EMORY PA CLINICAL OSCE 1462 CLIFTON RD NE ATLANTA, GA 30322

SPECIMEN INFORMATION: SPECIMEN: P121982AQW REQUISITION: 1979200-LAB REFERENCE #: H9000

COLLECTED: 12/17/12 RECEIVED: 12/17/12 REPORTED: 12/17/12

CBC (includes Diff/Plt)		Urinalysis (u/a)	
White blood cell count	9.0 3.8-10.8 Thousand/ μ L	color	Yellow
Red Blood Cell Count	4.6 F 4.2 - 5.4 M 4.6 - 6 million/mm ³	Appearance	clear
Hemoglobin	14 F 11-16 M 13.5 - 18g/dL	Specific Gravity	1.024
Hematocrit	42 F 35-45 M 40-54 %	pH	6
MCV	92.4 80.0-100.0 fl	Protein	Negative
MCH	31.6 27.0-33.0 pg	Glucose	Negative
MCHC	34.3 32.0-36.0 g/dL	Ketones	Negative
RDW	13.9 11.0-15.0 %	Bilirubin	Negative
Platelet Count	284 140-450 Thousand/ μ L	Blood	Negative
Neutrophils	67 40 -76%	Urobilinogen	0.2
Bands	4 0 - 5%	Nitrite	Negative
Lymphocytes	25 24 -44%	Leukocyte Esterase	Negative
Monocytes	3 3-7%	Microscopic	
Eosinophils	1 1-3%	WBCs/hpf	0
Basophils	0.2 0-1%	RBC/hpf	0
Other		Epithelial cells/hpf	0
Corrected Retic	2 2	Bacteria	0

Metabolic Profile	
Total Calcium	7.2 9 - 11 mg/dL
BUN	16 6 - 20 mg/dL
Creat	0.8 0.5 - 1.0 mg/dL
T.Bili	1.0 0.3 - 1.2 mg/dL
D. Bili	0.2 0 - 0.2 mg/dL
U. Bili	0.9 0.2 - 0.8 mg/dL
Alk Phos	44 32 - 103 IU/L
ALT	20 10 - 30 U/L
AST	9 8 - 46 U/L
Total Protein	7.5 6 - 8 g/dL
Albumin	3.5 3.4 - 4.8 g/dL
LDH	75 50 - 150 U/L
Sodium NA	140 136 - 145 mmol/L
Potassium K	4.0 3.6 - 5.1 mmol/L
Chloride CL	100 99 - 111 mmol/L
Bicarb CO2	24 22 - 32 mmol/L
Glucose	100 70 - 110 mg/dL

Coag	
aPTT	30.0 23.3 - 36.6 sec
PT	10.2 9.1 - 13.2 Sec
PT INR	1 0.82 - 1.18
D-Dimer	0.25 0.2 - .44 FEU
PFA	120 CEPI <164 s; GADP <116 s

Case #1


Hx - A 40-year-old truck driver presents with 1 month history of increasing fatigue, dyspnea on exertion, and increasing mid epigastric pain. No melena, hematemesis or PUD. His only medication use is daily "Goodys" powders for his chronic low back pain for 4 years. He does not smoke, use recreational drugs, and old drinks a few beers on the weekend.

Physical Exam- BP 126/78 not orthostatic, P 90 R 16 SpO2 96% on room air.

General Inspection – Spoon Nails, pallor, no jaundice.

HEENT, Chest, Heart, Abdomen WNL Rectal – Prostate normal and FOB positive

His lab slip is attached. What test would be indicated and the best treatment plan?





Case 1 Lab

Low Retic, Microcytic anemia
 Hb 9 (13.5)
 MCV 75 (80)
 Corrected retic 0.9 (2)
 Thrombocytosis – 550 (450)
 Normal CMP/ Lipase
 Normal UA
 Elevated D-Dimer 300
 Elevated PFA
 Normal PT/aPTT
 Positive FOB



SPECIMEN INFORMATION:
 SPECIMEN: P121982AQW
 REQUISITION: 1973200-
 LAB REFERENCE #: H9000

PATIENT INFORMATION:
 NAME: John Smith Age: 40
 GENDER: Male
 ID: 1.071.09
 PHONE:

Case 1

ORDERING PHYSICIAN: C. Johnson
 CLIENT INFORMATION:
 EMORY PA CLINICAL OSCE
 1462 CLIFTON RD NE
 ATLANTA, GA 30322

History: 1 month weakness, taking Goodys powders for chronic
 Low Back pain. Now mid epigastric pain

Test Name	Result	Reference Range	Urinalysis (u/A)	
HEMATOLOGY REPORT			color	Yellow
CBC			Appearance	clear
WHITE BLOOD CELL COUNT	9	3.8-10.8 THOUSAND/UL	Specific Gravity	1.024
RED BLOOD CELL COUNT	3.0 LOW	F 4.2 - 5.4 M 4.6 - 6 million/mm ³	pH	6
HEMOGLOBIN	9 LOW	F 11-16 M 13.5 - 18g/dL	Protein	Negative
HEMATOCRIT	27 LOW	F 35-45 M 40-54 %	Glucose	Negative
MCV	75 LOW	80.0-100.0 fL	Ketones	Negative
MCH	31.6	27.0-33.0 pg	Bilirubin	Negative
MCHC	34.3	32.0-36.0 g/dL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	Normal 0.2
PLATELET COUNT	550 HIGH	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	0.9 Low	2	Leukocyte Esterase	Negative
Metabolic Profile BMP			Microscopic	
Total Calcium	7.2	9 - 11 mg/dL	WBCs/hpf	0
BUN	16	6 - 20 mg/dL	RBC/hpf	0
Creat	0.8	0.5 - 1.0 mg/dL	Epithelial Cells/hpf	0
T Bili	1.0	0.3 - 1.2 mg/dL	Bacteria	0
D. Bili	0.1	0 - 0.2 mg/dL	Coag	
I. Bili	0.9	0.2 - 0.8 mg/dL	aPTT	27.5 23.3 - 36.6 sec
Alk Phos	44	32 - 103 IU/L	PT	10.1 9.1 - 13.2 Sec
ALT	20	10 - 30 U/L	PT INR	1 0.82 - 1.18
AST	9	8 - 46 U/L	D-Dimer	300 High < 250 µg/L
Total Protein	7.5	6 - 8 g/dL	PFA	300 High CEPI <164 s; CADP <116 s
Albumin	3.5	3.4 - 4.8 g/dL	Fecal Occult blood— Positive	
LDH	75	50 - 150 U/L	Amylase—	130 (23 - 140 U/L)
Sodium NA	140	136 - 145 mmol/L	Lipase—	100 (<160 U/L)
Potassium K	4.0	3.6 - 5.1 mmol/L		
Chloride CL	100	99 - 111 mmol/L		
Bicarb CO2	24	22 - 32 mmol/L		
Glucose	100	70 - 110 mg/dL		




Case 1 Question

- A. Order Vitamin B12 and Folate levels, Treat with PPI, change to long acting NSAID, Follow-up 1 month
- B. Order Iron studies with Ferritin, Treat with PPI change to acetaminophen for pain
- C. Stat Hematology consult for bone marrow biopsy
- D. Stat GI consult for upper and lower endoscopy

Anemia –Lab work-up


BPH = Bleeding/ Production/
Hemolysis



CRP = C-reactive protein for inflammation
 HbELP = hemoglobin electrophoresis
 TSH = Thyroid stimulation hormone
 UA = urinalysis

Microcytic workup

TICS – Thalassemia, Iron Deficiency, Chronic inflammation, Sideroblastic (Lead)





Anemia suspect


- Iron Deficiency because
 - Most common microcytic
 - GI bleeding – FOB positive
 - Spoon nails
 - Reactive thrombocytosis

What's in a Goody's???



Blood in the Tubing

PVC-pipes



- Platelets Adequate number that work right
- Von Willebrand Factor (vWF)
- Clotting Factors
- Pipes - Intact and healthy endothelium

Clotting Process



- Break in vessel wall – smooth muscle contracts
- Platelets with (vWF) stick to collagen and Activate
- More platelets are attracted
- Clotting Factors activate to form Fibrin
- Clot contracts

Von Willebrand Factor




- vWF


- Super glue of platelets to stick to damaged walls
- Stabilizes and transports Factor VIII
- Made by Endothelial Cells
- Most common genetic bleeding disorder

Platelets

- Made in the bone marrow
- Thrombopoietin made in liver stimulates production
- Fragments of megacaryocytes
- No nucleus
- 67% in circulation
- 33% in spleen storage
- Life 8 – 10 days




Activated Platelet




The Shape of Platelets


Flowing Platelets



Aggregated - Active Platelets



Courtesy of Helena Diagnostics



Case 1 Answer

- A. Order Vitamin B12 and Folate levels, Treat with PPI, change to long acting NSAID, Follow-up 1 month
- B. Order Iron studies with Ferritin, Treat with PPI change to acetaminophen for pain**
- C. Stat Hematology consult for bone marrow biopsy
- D. Stat GI consult for upper and lower endoscopy

Case 1 – NSAID (High PFA) induced gastric ulcer with bleeding (FOB +, High d-dimer from clotting) causing Fe deficient anemia (Microcytic with reactive thrombocytosis) Would check Ferritin, Stop NSAIDs, Give PPIs and F/U. Would do consult GI consult for endoscopy if still bleeding.

<http://www.aafp.org/afp/2012/0301/p469.html>

Case #2

Hx - A 50 year old factory worker presents with 2 days right calf tenderness and swelling. He has 1 month of feeling weak and non-vertigo dizziness. He has not had any injury, prolonged travel, or unusual exercise. He has a past history of hypertension diagnosed 20 years ago, but stopped medication after 1 year. He smokes 1 pack per day for 30 years, He does not use recreational drugs, and drinks a few beers on the weekend.

Physical Exam – BP is 178/104, P 90, R 16, SpO2 97%

General – Pallor and Lindsay's nails


HEENT – Funduscopy + A/V nicking, No thyromegally

Heart – No JVD, S1 S2 normal no Murmurs or Gallops

Abdomen – No bruits or organomegaly

Ext – R calf swelling and tenderness

His lab slip is attached. What is the most likely diagnosis?



Case #2 Labs



SPECIMEN INFORMATION:
SPECIMEN: F121982AQW
REQUISITION: 1973200-
LAB REFERENCE #: H9000

PATIENT INFORMATION:
NAME: John Smith Age: 50
GENDER: Male
ID: 1.071.09
PHONE:

Case 2
ORDERING PHYSICIAN: C. Johnson
CLIENT INFORMATION:
EMORY PA CLINICAL OSCE
1462 CLIFTON RD NE
ATLANTA, GA 30322

History: 1 month weak and dizzy, Has hypertension not treated well. Now right calf swelling and tender

Low Retic, Normocytic anemia
Hb 9 (13.5)
MCV 90 (80)
Corrected-retic 0.9 (2)
BUN/Creat elevated (33/2.1)
UA - Proteinuria 3+
Elevated D-Dimer
Elevated PFA
Normal PT/aPTT

Test Name	Result	Reference Range	Urinalysis (u/A)	
HEMATOLOGY REPORT			color	Yellow
CBC			Appearance	clear
WHITE BLOOD CELL COUNT	9	3.8-10.8 THOUSAND/UL	Specific Gravity	1.024
RED BLOOD CELL COUNT	3.0 LOW	F 4.2 - 5.4 M 4.6 - 6 mil	pH	6
HEMOGLOBIN	9 LOW	F 11-16 M 13.5 - 18g/dL	Protein	3+
HEMATOCRIT	27 LOW	F 35-45 M 40-54 %	Glucose	Negative
MCV	90	80.0-100.0 fL	Ketones	Negative
MCH	31.6	27.0-33.0 pg	Bilirubin	Negative
MCHC	34.3	32.0-36.0 g/dL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	0.2
PLATELET COUNT	284	140-450 Thousand /ul	Nitrite	Negative
Corrected Retic Count	0.9 Low	2	Leukocyte Esterase	Negative
			Microscopic	
			WBCs/hpf	0
			RBC/hpf	0
			Epithelial Cells/hpf	0
			Bacteria	0
RBC Morphology	Normal			
Metabolic Profile BMP				
Total Calcium	7.2	9 - 11 mg/dL		
BUN	33 High	6 - 20 mg/dL	Coag	
Creat	2.1 High	0.5 - 1.0 mg/dL	aPTT	30.0 23.3 - 36.6 sec
T Bili	1.0	0.3 - 1.2 mg/dL	PT	10.1 9.1 - 13.2 Sec
D. Bili	0.1	0 - 0.2 mg/dL	PT INR	1 0.82 - 1.18
I. Bili	0.9	0.2 - 0.8 mg/dL	D-Dimer	0.88 High 0.2 - .44 FEU
Alk Phos	44	20 - 90 U/L	PFA	240 High CEPI <164 s; CADP <116 s
ALT	20	10 - 30 U/L		
AST	9	8 - 46 U/L		
Total Protein	7.5	6 - 8 g/dL		
LDH	75	50 - 150 U/L		



Case #2 Question

- A. DVT and low epo anemia secondary to hypertension induced chronic renal failure
- B. DVT secondary to smoking and anemia from aplastic bone marrow
- C. Ruptured baker's cyst and anemia secondary to bleeding
- D. DVT and anemia from multiple myeloma

Renal Failure and clotting

- Early stages of CKD - Low protein C and antithrombin III, (anticlotting system) Increased fibrinogen, von Willebrand factor, factor VIII (pro thrombotic) Increased plasminogen activator inhibitor-1 (PAI-1), low tissue plasminogen activator (t-PA) So Clots stay
- End stage CKD - accumulating uremic toxins decrease platelet function, inhibiting their adhesion, aggregation and releasing platelet factors, such as serotonin or thromboxane A₂
- Damage to endothelial cells produce large amounts of prostacyclin (PGI₂) and nitric oxide (NO) inhibitor of platelet aggregation platelet adhesion.

Built in Clot Blockers and Busters

Intrinsic Pathway –
Inside the cut
Endothelial Injury

Test = aPTT

XII to XII active
XI to XI active
IX to IX active
VIII to VIII active

Liver made
Protein S
Protein C

Extrinsic Pathway –
outside the cut in the
plasma – Tissue Factor

Test = PT

VII to VII active

Tissue Factor
Pathway Inhibitor

Common Pathway

X to X active with V present

II Prothromin to Thrombin

I Fibrinogen to Fibrin


Antithrombin III

Plasminogen via t-PA/ PAI-1 to Plasmin

Fibrin split
products, D-Dimer

Endothelium

- Covers collagen, Tissue Factor (TF)
- vWF
- tPA
- Nitric Oxide (NO)
- Prostacyclin –Cox2 mediated
- ADPase
- TF Pathway Inhibitor (TFPI)
- Heparin
- Thrombomodulin – Binds free thrombin





Case #2 Answer

- A. DVT and low epo anemia secondary to hypertension induced chronic renal failure
- B. DVT secondary to smoking and anemia from aplastic bone marrow
- C. Ruptured baker's cyst and anemia secondary to bleeding
- D. DVT and anemia from multiple myeloma

Case 2 - Chronic renal failure (BUN/Creat, proteinuria) Anemia due to low epo, DVT due to hypercoagulable state and elevated PFA from platelet dysfunction. <http://ndt.oxfordjournals.org/content/29/1/29.long>



Case #3

- A 18 year old male high school student with Hemophilia A presents with 2 hour right knee swelling and pain. He has tried taking ibuprofen for pain relief. There was no injury. His lab slip is attached. What is the best treatment plan?

Case 3 Labs

Normal CBC
 Normal CMP
 Normal UA
 Normal D-Dimer
 Elevated PFA
 Prolonged aPTT
 Normal PT/INR
**Mixing study does not
 Correct the aPTT**




SPECIMEN INFORMATION:
 SPECIMEN: P121982AQW
 REQUISITION: 1973200-
 LAB REFERENCE #: H9000

PATIENT INFORMATION:
 NAME: John Smith Age: 18
 GENDER: Male
 ID: 1.071.09
 PHONE:

Case 3
 ORDERING PHYSICIAN: C. Johnson
 CLIENT INFORMATION:
 EMORY PA CLINICAL OSCE
 1462 CLIFTON Rd NE
 ATLANTA, GA 30322

History: Hemophilia A with new joint effusion and pain taking
 NSAID for the pain

Test Name	Result	Reference Range	Urinalysis (u/A)	
HEMATOLOGY REPORT			color	Yellow
CBC			Appearance	clear
WHITE BLOOD CELL COUNT	9	3.8-10.8 THOUSAND/uL	Specific Gravity	1.024
RED BLOOD CELL COUNT	4.4	F 4.2 - 5.4 M 4.5 - 6 million/mm ³	pH	6
HEMOGLOBIN	14	F 11-16 M 13.5 - 18g/oL	Protein	Negative
HEMATOCRIT	43	F 35-45 M 40-54 %	Glucose	Negative
MCV	85	80.0-100.0 fL	Ketones	Negative
MCH	28	27.0-33.0 pg	Bilirubin	Negative
MCHC	34	32.0-36.0 g/dL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	0.2
PLATELET COUNT	284	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	2	2	Leukocyte Esterase	Negative
			Microscopic	
			WBCs/hpf	0
			RBC/hpf	0
			Epithelial Cells/hpf	0
			Bacteria	0
RBC Morphology	Normal			
Metabolic Profile BMP			Coag	
Total Calcium	7.2	9 - 11 mg/dL	aPTT	47.5High 23.3 - 36.6 sec
BUN	10	6 - 20 mg/dL	PT	10.1 9.1 - 13.2 Sec
Creat	0.7	0.5 - 1.0 mg/dL	PT INR	1 0.82 - 1.18
T Bili	1.0	0.3 - 1.2 mg/dL	D-Dimer	0.25 0.2 - .44 FEU
D. Bili	0.1	0 - 0.2 mg/dL	PFA	240 High CEPI <164 s; CADP <116 s
I. Bili	0.9	0.2 - 0.8 mg/dL		
Alk Phos	44	20 - 90 U/L		Mixing study--aPTT does not correct 47.5
ALT	20	10 - 30 U/L		
AST	9	8 - 46 U/L		
Total Protein	7.5	6-8 g/dL		
LDH	100	50 - 150 U/L		



Case 3 Questions

- A. Recombinant Factor IX infusion
- B. Fresh Frozen Plasma transfusion
- C. Recombinant Factor VIII infusion
- D. Activated Factor VII infusion

Clotting Cascade - Factors

Intrinsic Pathway –
Inside the cut
Endothelial Injury

Test = aPTT

XII to XII active
XI to XI active
IX to IX active
VIII to VIII active

vWF stabilizes
Factor VIII

Calcium
needed as
co-factor

Extrinsic Pathway – outside the
cut in the plasma

Vitamin K - Liver dependant

Test = PT

VII to VII active + Tissue factor

Common Pathway

X to X active with V present

II Prothromin to Thrombin

I Fibrinogen to Fibrin

XIII to XIII active
stabilizer to crosslink
fibrin





Hemophilia

- US 13,320 cases of hemophilia A (VIII) and 3,640 cases of hemophilia B (IX).
- prolonged aPTT with a normal PT
- Bleeding into joints
- Treat with Recombinant Factor replacement (No longer plasma exposure)
- Three types of Hemophilia A – Genetic, vWD, Inhibitor to factor VIII acquired or developed

Emory University Physician
Assistant Program

Clotting Tests

Intrinsic Pathway –
Inside the cut
Endothelial Injury

Test = aPTT

XII to XII active
XI to XI active
IX to IX active

VIII to VIII active

Common Pathway Test = TT

X to X active with V present

II Prothrombin to Thrombin

I Fibrinogen to Fibrin

Extrinsic Pathway –
outside the cut in the
plasma – Tissue Factor

Test = PT

VII to VII active




Tests to Order – Screen for Clotting ability

- **PT** -Prothrombin Time - +/- 2 of control = 11 - 16 sec. Extrinsic system monitor for coumadin therapy. INR is International Normalization Ratio, 1 is normal, 2- 3 for Coumadin Therapy, 2.5 - 3.5 if heart valve
- **aPTT** - activated Partial Thromboplastin Time- 25 - 38 sec. Intrinsic system. Used to monitor Heparin therapy (if abnormal do Factor analysis and consider vWD)
- **Mixing Study** (add normal plasma to patient plasma re do PT and aPTT) – if PT or aPTT **do not** correct then there is a inhibitor present and not a factor deficiency.
- **TT** – Thrombin Time measures the common pathway

Coag Test Summary

PT	aPTT	Differential diagnosis
Prolonged	Normal	Factor VII deficiency or inhibitor, vitamin k deficiency, liver disease, warfarin therapy
Normal	Prolonged	Factor VIII, IX, XI, XII deficiency or inhibitor; von Willebrand disease; lupus anticoagulant; heparin therapy
Prolonged	Prolonged	Prothrombin, fibrinogen, Factor V or X deficiency; liver disease; disseminated intravascular coagulation; combined heparin and warfarin therapy Need TT Thrombin Time



Case 3 Answer

- A. Recombinant Factor IX infusion
- B. Fresh Frozen Plasma transfusion
- C. Recombinant Factor VIII infusion
- D. Activated Factor VII infusion**

Case 3 – Prolonged aPTT that does not correct with a mixing study- most likely inhibitors to Factor VIII

<https://emedicine.medscape.com/article/779322-treatment>

<https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html>



Case #4

- A 40 year old homeless alcoholic male presents with 1 week increasing jaundice, 3 days nausea and vomiting, 1 day vomiting blood. He smokes about 1 pack per week for 20 years, He does not use recreational drugs, and old drinks a fifth of whiskey a day. His lab slip is attached. What is the cause of the abnormal coagulation studies?

Case 4 Labs



SPECIMEN INFORMATION:
SPECIMEN: P121982ACQW
REQUISITION: 1973200-
LAB REFERENCE #: H9000

PATIENT INFORMATION:
NAME: John Smith Age: 40
GENDER: Male
ID: 1.071.09
PHONE:

Case 4
ORDERING PHYSICIAN: C. Johnson
CLIENT INFORMATION:
EMORY PA CLINICAL OSCE
1462 CLIFTON RD NE
ATLANTA, GA 30322

History: 3 days nausea , 1 day vomiting blood, 1 week jaundice, admits to excessive ETOH

Normal Retic Macrocytic anemia
Hb 10 (13.5)
MCV 106 (80)
C-retic 2 (2)
Thrombocytopenia – 110 (140)
ETOH hepatitis AST/ALT 1/2
UA – Ketones, Bili, Urobilinogen
Elevated D-Dimer
Normal PFA
Prolonged PT/aPTT
Positive FOB
Normal Amylase/Lipase

Test Name	Result	Reference Range	Urinalysis (u/A)	
HEMATOLOGY REPORT			color	Yellow
CBC			Appearance	clear
WHITE BLOOD CELL COUNT	9	3.8-10.8 THOUSAND/UL	Specific Gravity	1.024
RED BLOOD CELL COUNT	3.2 LOW	F 4.2 - 5.4 M 4.6 - 6 million/mm ³	pH	6
HEMOGLOBIN	10 LOW	F 11-16 M 13.5 - 18g/dL	Protein	Negative
HEMATOCRIT	30 LOW	F 35-45 M 40-54 %	Glucose	Negative
MCV	106 HIGH	80.0-100.0 fL	Ketones	Positive
MCH	31.6	27.0-33.0 pg	Bilirubin	3+Positive
MCHC	34.3	32.0-36.0 g/dL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	3+Positive
PLATELET COUNT	110 LOW	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	2	2	Leukocyte Esterase	Negative
Metabolic Profile BMP			Microscopic	
Total Calcium	7.2	9 - 11 mg/dL	WBCs/hpf	0
BUN	16	6 - 20 mg/dL	RBC/hpf	0
Creat	0.8	0.5 - 1.0 mg/dL	Epithelial Cells/hpf	0
T Bili	5.0 H	0.3 - 1.2 mg/dL	Bacteria	0
D. Bili	4.1 H	0 - 0.2 mg/dL		
I. Bili	0.9 H	0.2 - 0.8 mg/dL		
Alk Phos	100	92 - 103 IU/L		
ALT	300 H	10 - 30 U/L		
AST	620 H	8 - 46 U/L		
Total Protein	5.5 L	6 - 8 g/dL		
Albumin	3.2 L	3.4 - 4.8 g/dL		
LDH	175 H	50 - 150 U/L		
Sodium NA	140	136 - 145 mmol/L		
Potassium K	4.0	3.6 - 5.1 mmol/L		
Chloride Cl	90 L	99 - 111 mmol/L		
Bicarb CO2	38 H	22 - 32 mmol/L		
Glucose	100	70 - 110 mg/dL		
			Coag	
			aPTT	37.5 H 23.3 - 36.6 sec
			PT	14 H 9.1 - 13.2 Sec
			PT INR	1.22 H 0.82 - 1.18
			D-Dimer	400 H <250 µg/L
			PFA	90 norm CEPI <164 s; CADP <116 s

Fecal Occult blood— Positive

Amylase— 130 (23-140 U/L)

Lipase—100 (<160 U/L)



Case 4 Question

- A. Alcoholic Hepatitis and cirrhosis cause all clotting factors to be inactive
- B. Alcoholic Hepatitis and cirrhosis cause all clotting factors to be low in production
- C. Whiskey inhibits platelet activation
- D. Low platelets cause clotting factor deficiencies



Liver Disease

- The liver is THE site for coagulation factor synthesis (except Factor VIII is liver and endothelium)
- multi-factorial coagulopathy
 - Decreased coagulation factors
 - Decreased anti-coagulation factors
 - Decreased fibrinogen
 - Decreased platelets (liver makes thrombopoietin)
 - Increased D-dimers (interfere with clot formation)
- Bleeding from liver failure is a major cause morbidity and mortality
- Give Vitamin K and/or FFP



Case 4 Answer

- A. Alcoholic Hepatitis and cirrhosis cause all clotting factors to be inactive
- B. Alcoholic Hepatitis and cirrhosis cause most clotting factors and platelets to be low in production**
- C. Whiskey inhibits platelet activation
- D. Low platelets cause clotting factor deficiencies

Case 4 - Alcoholic Hepatitis AST/ALT ratio 2/1, Anemia with low Retic High MCV probably due to folate def. High D/I bili, high PT because of Liver insult (Low clotting factor production low protein/albumin) high d-dimer because of clotting to stop bleeding. Urobilinogen and Bili in urine all high (Urobilinogen is Direct Bili transformed by gut bacteria and reabsorbed- If no Urobilinogen in urine but high Bilirubin – think biliary obstruction. Metabolic alkalosis from vomiting. Low platelets from liver insult-low thrombopoietin

<http://emedicine.medscape.com/article/170539-overview>



Case #5

- A 60 year old retired male presents with 1 month increasing weakness, dyspnea on exertion, increasing low back pain and 2 days of left calf swelling with tenderness. He does not smoke, use recreational drugs, or drink alcohol. His lab slip is attached. What is the most likely diagnosis?

Case 5 Labs

CBC- Pancytopenia
 WBC 1.9 (3.8)
 Hb 9 (15)
 Plt 90 (140)
 Low Retic 0.9 (2)
 Micro: Rouleaux formations
 CMP – hypercalcemia 12.2
 Elevated protein 9.5
 UA Protenuria 2+
 Coag – elevated d-dimer



Specimen Information:
 Specimen: P121982AQW
 Requisition: 1973200
 Lab reference #: H9000
 Collected: 12/17/12
 Received: 12/17/12
 Reported: 12/17/12

Patient Information:
 Name: John Smith Age: 60
 Gender: Male
 ID: 1.071.09
 Phone:

Case 5
 Ordering Physician: C. Johnson
 Client Information:
 Emory PA Clinical OSCE
 1462 Clifton Rd NE
 Atlanta, GA 30322

1 month increasing weakness, low back pain, and new DVT

Test Name	Result	Reference Range
Hematology Report		
CBC		
White blood cell count	1.9 Low	3.8-10.8 Thousand/uL
Red Blood Cell Count	3.0 low	F 4.2 - 5.4 M 4.6 - 5 mil
Hemoglobin	9 Low	F 11-16 M 13.5 - 18g/dL
Hematocrit	27 Low	F 35-45 M 40-54 %
MCV	82	80.0-100.0 fL
MCH	24 Low	27.0-32.0 pg
MCHC	24.3Low	32.0-36.0 g/dL
RDW	13.9	11.0-15.0 %
Platelet Count	90 Low	140-450 Thousand /uL
Corrected Retic Count	0.9 Low	2
	Rouleaux formations	
RBC Morphology		

Urinalysis (u/A)	
color	Yellow
Appearance	Clear
Specific Gravity	1.024
pH	6
Protein	2+ Positive
Glucose	Negative
Ketones	Negative
Bilirubin	Negative
Blood	Negative
Urobilinogen	0.2
Nitrite	Negative
Leukocyte Esterase	Negative
Microscopic	
WBCs/hpf	0
RBC/hpf	0
Epithelial Cells/hpf	0
Bacteria	0

Metabolic Profile BMP			
Total Calcium	12.2High	9 - 11 mg/dL	Coag
BUN	16	6 - 20 mg/dL	aPTT
Creat	0.8	0.5 - 1.0 mg/dL	PT
T.Bili	1.0	0.3 - 1.2 mg/dL	PT INR
D. Bili	0.1	0 - 0.2 mg/dL	D-Dimer
L. Bili	0.9	0.2 - 0.8 mg/dL	PFA
ALK Phos	44	20 - 90 U/L	
ALT	20	10 - 30 U/L	
AST	9	8 - 46 U/L	
Total Protein	9.5 High	6 - 8 g/dL	
LDH	75	50 - 150 U/L	

27.5	23.3 - 36.6 sec
10.1	9.1 - 13.2 Sec
1	0.82 - 1.18
500 H	< 250 µg/L DDU
110	CEPI <164 s; CADP <116 s





Case 5 Question

- A. Chronic Lymphocytic Leukemia with DVT
- B. Non Hodgkin's Lymphoma with DVT
- C. Multiple Myeloma with DVT
- D. Metastatic Lung cancer with DVT

Multiple Myeloma

- Symptoms and Signs - Itching, Bone pain, weakness, anemia, lytic bone lesions, increased protein, M - Spike, Bence Jones protein in urine, renal failure, rouleaux formation



Emory University Physician
Assistant Program



Case 5 Answer

- A. Chronic Lymphocytic Leukemia with DVT
- B. Non Hodgkin's Lymphoma with DVT
- C. Multiple Myeloma with DVT**
- D. Metastatic Lung cancer with DVT

Case 5 – Multiple Myeloma with increased serum and urine protein – would confirm with SPEP and Urine for Bence Jones protein. Oncology referral for Bone Marrow Bx. Anemia and low platelets from marrow replacement with plasma cells. DVT because MM is a hypercoagulable state.

<http://asheducationbook.hematologylibrary.org/content/2007/1/158.full>

Case #6



- A 60 year old retired male presents with 3 months increasing weakness, dyspnea on exertion, and gum bleeding after brushing his teeth. He does not smoke, use recreational drugs, or drink alcohol . His lab slip is attached. What is the most likely diagnosis?

Case 6 Labs

CBC – Leukocytosis 30.9 (10.8)
 Low Retic, Microcytic anemia
 Hb 9 (13.5)
 MCV 70 (80)
 C-retic 0.9 (2)
 Low Platelets 90 (140)
 Mature Lymphocytes on smear
 CMP - Normal
 UA - Negative
 COAG - Normal



Specimen Information:
 Specimen: P121982AQW
 Requisition: 1973200
 Lab reference #: H9000

Collected: 12/17/12
 Received: 12/17/12
 Reported: 12/17/12

Patient Information:
 Name: John Smith Age: 60
 Gender: Male
 ID: 1.071.09
 Phone:

Case 6

Ordering Physician: C. Johnson
 Client Information:
 Emory PA Clinical OSCE
 1462 Clifton Rd NE
 Atlanta, GA 30322

3 months progressive weakness and gum
 bleeding after brushing

Test Name	Result	Reference Range	Urinalysis (u/A)	
Hematology Report			Color	Yellow
CBC			Appearance	Clear
White blood cell count	30.9 High	3.8-10.8 Thousand/uL	Specific Gravity	1.024
Red Blood Cell Count	3.0 Low	F 4.2 - 5.4 M 4.6 - 6 million/mm ³	pH	6
Hemoglobin	9 Low	F 11-16 M 13.5 - 18g/dL	Protein	Negative
Hematocrit	27 Low	F 35-45 M 40-54 %	Glucose	Negative
MCV	70 Low	80.0-100.0 fL	Ketones	Negative
MCH	24 Low	27.0-33.0 pg	Bilirubin	Negative
MCHC	24.3 Low	32.0-36.0 g/dL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	0.2
Platelet Count	90 Low	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	0.9 Low	2	Leukocyte Esterase	Negative
Mature Lymphocytes predominate			Microscopic	
RBC Morphology			WBCs/hpf	0
			RBC/hpf	0
			Epithelial Cells/hpf	0
			Bacteria	0

Metabolic Profile BMP				
Total Calcium	10.0	9 - 11 mg/dL		
BUN	16	6 - 20 mg/dL		
Creat	0.8	0.5 - 1.0 mg/dL	Coag	
T.Bili	1.0	0.3 - 1.2 mg/dL	aPTT	27.5 23.3 - 36.6 sec
D. Bili	0.1	0 - 0.2 mg/dL	PT	10.1 9.1 - 13.2 Sec
L.Bili	0.9	0.2 - 0.8 mg/dL	PT INR	1 0.82 - 1.18
Alk Phos	44	20 - 90 U/L	D-Dimer	100 < 250 µg/L DDU
ALT	20	10 - 30 U/L	PFA	110 CEPI <164 s; CADP <116 s
AST	9	8 - 46 U/L		
Total Protein	9.5	6 - 8 g/dL		
LDH	75	50 - 150 U/L		



Case 6 Question

- A. Chronic Lymphocytic Leukemia
- B. Non Hodgkin's Lymphoma
- C. Multiple Myeloma
- D. Acute Lymphocytic Leukemia

Bleeding: think PVC

Pipes





PVC pipes

■ Platelets

- Not enough below 50,000 – production, destruction, sequestration
- Not working –ASA, NSAIDs, Uremia, Congenital

■ Von Willebrands Disease-Type 1 most common

■ Clotting Factors

- Most common: VIII, IX
- Vitamin K Deficiency, Liver Disease

■ Pipes - Vasculitis, Scurvy, Ehlers-Danlos, Hereditary Hemorrhagic Telangiectasias, Steroids


- Palpable Purpura – Sepsis, Meningococemia, Henoch-Schonlein purpura, Drugs

Bleeding Test- PVC- Pipes

- Platelets – CBC platelet count
 - Do they work – PFA (Bleeding time)
- vWF – abnormal PFA and aPTT (Factor VIII depends of vWF) do vWF analysis
- Clotting Factors – PT and aPTT if either abnormal – do Mixing study – if corrects do Factor levels VIII, IX. If both PT and aPTT abnormal do TT Thrombin time
- CMP, UA (Renal or Hepatic causes)
- Pipes – Vasculitis C-Reactive Protein, ESR, Biopsy




CLL



Emory University Physician
Assistant Program

ALL



Emory University Physician
Assistant Program



Leukemia

- ALL: Acute Lymphocytic Leukemia (Usually in Children)
- AML: Acute Myelogenous Leukemia
- CLL: Chronic Lymphocytic Leukemia (Usually Adults – minimal symptoms)
- CML: Chronic Myelogenous Leukemia

- HX: Fatigue, anorexia, wt loss, fever, bone pain, headaches, lymphadenopathy, non healing infections, thrush, bleeding (Nose, gums, GI, menses)
- PE: Pallor, gingival hyperplasia, Candida infections, lymphadenopathy, hepatosplenomegaly, lung infiltrates, bleeding, bruising
- LAB: CBC: elevated WBC/ low platelets, low Hct, WBC Differential, Chem 18, Bone Marrow Biopsy
- Philadelphia Chromosome seen in CML
- Auer bodies or rods in AML
- CT - MRI chest and abdomen
- CXR - Chest infiltration, pneumonias
- RX: Chemotherapy, Bone Marrow Transplant

Emory University Physician
Assistant Program



Case 6 Answer

A. Chronic Lymphocytic Leukemia

B. Non Hodgkin's Lymphoma

C. Multiple Myeloma

D. Acute Lymphocytic Leukemia

Case 6 – CLL – Low Hb and Platelets with high WBCs mainly mature Lymphs. Refer to oncology for Bone Marrow Biopsy and monitoring
<http://emedicine.medscape.com/article/199313-overview>



Case #7

- A 28 year old female nurse presents with 1 year of heavy menses, increasing weakness,. She does not smoke, use recreational drugs, or drink alcohol. Her physical exam including pelvic is normal. Her lab slip is attached. What is the most likely cause of her anemia?

Case 7 Labs

CBC

Low Retic, Microcytic anemia

Hb 9 (13.5)

MCV 70 (80)

C-retic 0.9 (2)

Normal Platelets 284 (140)

CMP - Normal

UA - Negative

Coag - Elevated PFA

Prolonged aPTT that corrects
with mixing study



Specimen information:
Specimen: P121982ACW
Requisition: 1973200-
Lab reference #: H9000

Collected: 12/17/13
Received: 12/17/13
Reported: 12/17/13

Patient Information:

Name: Sally Jones Age: 28
Gender: Female
ID: 1.071.09
Phone:

Case 7

Ordering Physician: C. Johnson

Client Information:

Emory PA Clinical OSCE
1452 Clifton Rd NE
Atlanta, GA 30322

History: Heavy menses,

Test Name	Result	Reference Range
Hematology Report		
CBC		
White blood cell count	9	3.8-10.8 Thousand/uL
Red Blood Cell Count	3.0 Low	F 4.2 - 5.4 M 4.5 - 6 mil
Hemoglobin	9 Low	F 11-16 M 13.5 - 18g/dL
Hematocrit	27 Low	F 35-45 M 40-54 %
MCV	70 Low	80.0-100.0 fL
MCH	24 Low	27.0-33.0 pg
MCHC	24.3Low	32.0-36.0 g/cL
RDW	13.9	11.0-15.0 %
Platelet Count	284	140-450 Thousand /uL
Corrected Retic Count	0.9 Low	2
RBC Morphology		
	Microcytes,	

Metabolic Profile BMP		
Total Calcium	7.2	9 - 11 mg/dL
BUN	10	6 - 20 mg/dL
Creat	0.7	0.5 - 1.0 mg/dL
T Bili	1.0	0.3 - 1.2 mg/dL
D. Bili	0.1	0 - 0.2 mg/dL
U. Bili	0.9	0.2 - 0.8 mg/dL
Alk Phos	44	20 - 90 U/L
ALT	20	10 - 30 U/L
AST	9	8 - 46 U/L
Total Protein	7.5	6 - 8 g/dL
LDH	100	50 - 150 U/L

Urinalysis (u/A)	
color	Yellow
Appearance	clear
Specific Gravity	1.024
pH	6
Protein	Negative
Glucose	Negative
Ketones	Negative
Bilirubin	Negative
Blood	Negative
Urobilinogen	0.2
Nitrite	Negative
Leukocyte Esterase	Negative
Microscopic	
WBCs/hpf	0
RBC/hpf	0
Epithelial Cells/hpf	0
Bacteria	0

Coag		
aPTT	47...5High	23.3 - 36.6 sec
PT	10.1	9.1 - 13.2 Sec
PT INR	1	0.82 - 1.18
D-Dimer	0.25	0.2 - .44 FEU
PFA	240 High	CEPI <164 s; CADP <116 s

Mixing study— aPTT corrects to 30.0 sec



Case 7 Question

- A. Iron Deficiency secondary to fibroids
- B. Thalassemia minor
- C. Iron deficiency and Von Willebrand Disease
- D. Lead toxicity

Clotting Tests for bleeding

Test/Disease	PT	aPTT	PFA	Platelet Ct
vWD	Normal	Increased	Abnormal	Normal
Hemophilia A/B heparin, lupus	Normal	Increased	Normal	Normal
DIC	Increased	Increased	Abnormal	Low
Uremia	Normal	Normal	Abnormal	Normal
Aspirin NSAIDs	Normal	Normal	Abnormal	Normal
Early: Liver Dz Vit K def, F VII coumadin	Increased	Normal	Normal	Normal
Late Liver Dz	Increased	Increased	Normal	Low
ITP, TTP, HUS, HIT	Normal	Normal	Normal	Low



Von Willebrand Disease

- Most common inherited bleeding disorder
- Found in approximately 1% of the population
- Most individuals are asymptomatic unless a significant bleeding event occurs
- Blood Group O individuals have significantly lower vWF than other groups (30% lower)
- vWF stabilizes Factor VIII so any decrease in vWF will increase aPTT and platelet function analysis will be abnormal



Von Willebrand Disease

- Measure vWF antigen (vWF:Ag)
 - How much protein is present?
- Measure vWF activity (Ristocetin Cofactor)
 - How well is the protein working?
- Measure Factor VIII activity
 - How well is vWF stabilizing Factor VIII?
- Evaluate pattern of von Willebrand multimers by electrophoresis
 - Important for classification of disease (6 types) and therapeutic management
- Treat most common cause with DDAVP



Case 7 Answer

- A. Iron Deficiency secondary to fibroids
- B. Thalassemia minor
- C. Iron deficiency and Von Willebrand Disease**
- D. Lead toxicity

Case 7 – Menorrhagia from Von Willebrand disease (VWD) with elevated aPTT (not stabilizing Factor VIII and abnormal PFA (super glue of Platelets) Iron def anemia (Microcytic low retic)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874860/>



Case #8

- A 13-year-old healthy male presents with 2 days of recurrent gum bleeding and nosebleeds. He had a viral syndrome over 1 week ago that resolved. No other positives in his medical history. On PE he has petechiae and purpura on his chest and legs. His lab slip is attached. What is the most likely cause of his symptoms?

Petechea and Purpura



Case 8 Labs



Patient Information:
Name: John Smith Age: 13
Gender: Male
ID: 1.071.09
Phone:

Case 8

Ordering Physician: C. Johnson
Client Information:
Emory PA Clinical OSCE
1462 Clifton Rd NE
Atlanta, GA 30322

Specimen Information:
Specimen: P121982AQW
Requisition: 1975200-
Lab reference #: H9000

Collected: 12/17/12
Received: 12/17/12
Reported: 12/17/12

History: Bleeding gums and nose post viral infection 1 week ago

CBC – Thrombocytopenia 20 (140)
CMP - Normal
UA - Negative
Coag – Normal PFA
Normal PT/aPTT

Test Name	Result	Reference Range	UrinAnalysis (u/A)	
Hematology Report			color	Yellow
CBC			Appearance	clear
White blood cell count	9	3.8-10.8 Thousand/uL	Specific Gravity	1.024
Red Blood Cell Count	4.4	F 4.2 - 5.4 M 4.5 - 6 mil	pH	6
Hemoglobin	14	F 11-16 M 13.5 - 18g/dL	Protein	Negative
Hematocrit	43	F 35-45 M 40-54 %	Glucose	Negative
MCV	85	80.0-100.0 fL	Ketones	Negative
MCH	28	27.0-33.0 pg	Bilirubin	Negative
MCHC	34	32.0-36.0 g/dL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	0.2
Platelet Count	20 Low	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	2	2	Leukocyte Esterase	Negative
			Microscopic	
	Normal		WBCs/hpf	0
			RBC/hpf	0
RBC Morphology			Epithelial Cells/hpf	0
			Bacteria	0

Metabolic Profile BMP		
Total Calcium	7.2	9 - 11 mg/dL
BUN	10	6 - 20 mg/dL
Creat	0.7	0.5 - 1.0 mg/dL
T.Bili	1.0	0.3 - 1.2 mg/dL
D. Bili	0.1	0 - 0.2 mg/dL
U. Bili	0.9	0.2 - 0.8 mg/dL
Alk Phos	44	20 - 90 U/L
ALT	20	10 - 30 U/L
AST	9	8 - 46 U/L
Total Protein	7.5	6 - 8 g/dL
LDH	100	50 - 150 U/L

Coag		
aPTT	27.5	23.3 - 36.6 sec
PT	10.1	9.1 - 13.2 Sec
PT INR	1	0.82 - 1.18
D-Dimer	0.25	0.2 - .44 FEU
PFA	90 norm	CEPI <164 s; CADP <116 s



Case 8 Question

- A. Chronic Lymphocytic Leukemia
- B. Non Hodgkins Lymphoma
- C. Mononucleosis
- D. Immune Thrombocytopenic Purpura



Thrombocytopenia

- Production
 - Nutritional B12 or Folate Deficiency
 - Congenital – Alports syndrome, Fanconi anemia, Wiscott-Aldrich syndrome
 - Marrow damage – aplastic anemia, chemotherapy, drugs, malignancy – myeloma or leukemia, radiation, myelodysplasia
- Destruction
 - Immune – (Positive Platelet Associated Antibody test or HIT assay) ITP, Drug, HIV, SLE, HIT
 - Non-Immune- DIC, TTP, Preeclampsia, HELLP syndrome
Anti-phospholipid syndrome
- Sequestration- Liver, spleen, marrow -myelofibrosis, cancer



Platelets - How Low Can you go?

- 150,000 - 350,000 cu/mm Normal
- 80 – 100 – need for surgery
- 40 – 50 for procedures like LP
- 10 – 40 –At risk if trauma or surgery
- < 10,000 spontaneous bleeding
- if > 1 million - Clotting too much

Thrombocytopenia

Testing



- Liver Spleen size – Ultrasound or CT
- Bone Marrow Biopsy
- Platelet antibodies (direct and indirect)
- HIT assay if on heparin
- ADAMTS 13 (TTP)
- Blood smear (morphology)
- Antibody response to *Escherichia coli* O157:H7



ITP - Immune Thrombocytopenic Purpura

- In children linked to viral infection
 - platelet-associated antibodies
 - 80% rapid remission, and does not recur
 - Treatment: steroids and IVIG
 - 10% to 20% develop chronic ITP
 - splenectomy works in 70%
- Adults linked to HIV and Hep C
 - 50% develop chronic ITP
 - Same treatments

There is a song for that

**Friends With Low Platelets | Garth Brooks Parody |
ZDoggMD.com**

<https://www.youtube.com/watch?v=-rwcIRfHcAE>





Case 8 Answer

- A. Chronic Lymphocytic Leukemia
- B. Non Hodgkins Lymphoma
- C. Mononucleosis
- D. Immune Thrombocytopenic Purpura**

Case 8 - ITP post viral syndrome. Can watch and wait with frequent CBC follow-ups. The American Society of Hematology (ASH) recommends that children who have no bleeding or minor bleeding (eg, cutaneous manifestations such as bruising and petechiae) be managed with observation alone regardless of platelet count. ^[8]

<http://emedicine.medscape.com/article/202158-overview>

<https://ashpublications.org/bloodadvances/article/3/23/3829/429213>



Case #9

- A 25 year old male graduate student is admitted for his second unprovoked DVT and is now being treated day 2 with unfractionated heparin by IV pump. His lab slip is attached. What lab test would be most likely positive?

Case 9 Labs



SPECIMEN INFORMATION:
SPECIMEN: P121982AQW
REQUISITION: 1973200-
LAB REFERENCE #: H9000

PATIENT INFORMATION:
NAME: John Smith Age: 25
GENDER: Male
ID: 1.071.09
PHONE:

Case 9

ORDERING PHYSICIAN: C. Johnson
CLIENT INFORMATION:
EMORY PA CLINICAL OSCE
1462 CLIFTON RD NE
ATLANTA, GA 30322

History: admitted for second unprovoked DVT on UFH and NSAID


CBC
Normal Platelets 284 (140)
CMP - Normal
UA - Negative
Coag - Elevated PFA
Prolonged aPTT that corrects
with mixing study
Elevated D-Dimer

Test Name	Result	Reference Range	Urinalysis (u/A)	
HEMATOLOGY REPORT			color	Yellow
CBC			Appearance	clear
WHITE BLOOD CELL COUNT	9	3.8-10.8 THOUSAND/UL	Specific Gravity	1.024
RED BLOOD CELL COUNT	4.4	F 4.2 - 5.4 M 4.6 - 6 million/mm ³	pH	6
HEMOGLOBIN	14	F 11-16 M 13.5 - 18g/oL	Protein	Negative
HEMATOCRIT	43	F 35-45 M 40-54 %	Glucose	Negative
MCV	85	80.0-100.0 fl	Ketones	Negative
MCH	28	27.0-33.0 pg	Bilirubin	Negative
MCHC	34	32.0-36.0 g/cL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	0.2
PLATELET COUNT	284	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	2	2	Leukocyte Esterase	Negative
RBC Morphology	Normal		Microscopic	
			WBCs/hpf	0
			RBC/hpf	0
			Epithelial Cells/hpf	0
			Bacteria	0
Metabolic Profile BMP			Coag	
Total Calcium	7.2	9 - 11 mg/dL	aPTT	47.5High 23.3 - 36.6 sec
BUN	10	6 - 20 mg/dL	PT	10.1 9.1 - 13.2 Sec
Creat	0.7	0.5 - 1.0 mg/dL	PT INR	1 0.82 - 1.18
T Bili	1.0	0.3 - 1.2 mg/dL	D-Dimer	400 H < 250 ug/L
D. Bili	0.1	0 - 0.2 mg/dL	PFA	240 High CEPI <164 s; CADP <116 s
I. Bili	0.9	0.2 - 0.8 mg/dL		
Alk Phos	44	20 - 90 U/L		
ALT	20	10 - 30 U/L		
AST	9	8 - 46 U/L		
Total Protein	7.5	6 - 8 g/dL		
LDH	100	50 - 150 U/L		



Case 9 Question

- A. Elevated homocysteine level
- B. Positive Factor V Leiden
- C. Low antithrombin III
- D. Antiphospholipid (anticardiolipin) antibody




Best screening test for hypercoagulability?

- There is none!!
- Unprovoked clot is the first clue
- More than one clot suggests a genetic issue
- Start testing for most common

Tests – Is Clotting going on?

- D-Dimer elevation – from thrombolysis (break apart)
 - Also used to know when to stop anticoagulant therapy
- Fibrin Split products
- Peripheral smear may show schistocytes (helmet cells)
- <https://ashpublications.org/blood/article/124/2/196/32915/D-dimer-to-guide-the-duration-of-anticoagulation>



Tests – Clotting too much recurrent DVT/PE

- Fasting homocysteine level/ MTHFR gene
- Factor V Leiden assay
- Protein S, C, antithrombin III assay
- Lupus anticoagulant
- Anticardiolipin antibodies
- Anti Beta-GPI antibodies
- Prothrombin 20210 mutation test
- Fibrinogen level
- HIT Assay if Heparin exposure

Prevalence and Relative Risk of Clotting problem DVT/PE

- Hyperhomocysteinemia/ MTHFR gene (10% -15%) RR=3
- **Factor V Leiden (5% Most common genetic)** RR=7-80
- Platelet GPIIb/IIIa Human Platelet Antigen -HPA-1b (2 - 3%) RR = 4
- Prothrombin 20210 mutation (1- 2%) RR=2-5
- Protein C deficiency (0.2 – 0.5%) RR=7
- Protein S deficiency (0.1%) RR= 8.5
- Antithrombin III deficiency (0.2 – 0.5%) RR=8

- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056464/>
- <https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines>



Case 9 Answer

A. Elevated homocysteine level

B. Positive Factor V Leiden

C. Low antithrombin III

D. Antiphospholipid (anticardiolipin) antibody

Case 9 – Factor V Leiden is the most common genetic cause of hypercoagulable states and may need lifelong anticoagulation
<http://emedicine.medscape.com/article/211039-overview>



Case #10

- A 30-year-old male had ACL repair on his right knee 5 days ago, developed a DVT post op day 1 and has been in the hospital receiving unfractionated heparin by IV infusion pump. His lab slip is attached for post-op day 6. What is the most appropriate order to write?

Case 10 Labs



SPECIMEN INFORMATION:
SPECIMEN: P121982AQW
REQUISITION: 1973200-
LAB REFERENCE #: H9000

PATIENT INFORMATION:
NAME: John Smith Age: 30
GENDER: Male
ID: 1.071.09
PHONE:

Case 10
ORDERING PHYSICIAN: C. Johnson
CLIENT INFORMATION:
EMORY PA CLINICAL OSCE
1462 CLIFTON RD NE
ATLANTA, GA 30322

History: 5 days after Knee surgery Diagnosis of PE treated with Unfractionated Heparin for 4 days

CBC – Thrombocytopenia 90 (140)
CMP - Normal
UA - Negative
Coag – Normal PFA
Elevated aPTT
Elevated D-Dimer

Test Name	Result	Reference Range	Urinanalysis (u/A)	
HEMATOLOGY REPORT			color	Yellow
CBC			Appearance	clear
WHITE BLOOD CELL COUNT	9	3.8-10.8 THOUSAND/UL	Specific Gravity	1.024
RED BLOOD CELL COUNT	4.4	F 4.2 - 5.4 M 4.6 - 6 million/mm3	pH	6
HEMOGLOBIN	14	F 11-16 M 13.5 - 18g/dL	Protein	Negative
HEMATOCRIT	43	F 35-45 M 40-54 %	Glucose	Negative
MCV	85	80.0-100.0 fL	Ketones	Negative
MCH	28	27.0-33.0 pg	Bilirubin	Negative
MCHC	34	32.0-36.0 g/dL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	0.2
PLATELET COUNT	90 Low	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	2	2	Leukocyte Esterase	Negative
RBC Morphology			Microscopic	
Normal			WBCs/hpf	0
			RBC/hpf	0
			Epithelial Cells/hpf	0
			Bacteria	0
Metabolic Profile BMP			Coag	
Total Calcium	7.2	9 - 11 mg/dL	aPTT	47.5High 23.3 - 36.6 sec
BUN	10	6 - 20 mg/dL	PT	10.1 9.1 - 13.2 Sec
Creat	0.7	0.5 - 1.0 mg/dL	PT INR	1 0.82 - 1.18
T Bili	1.0	0.3 - 1.2 mg/dL	D-Dimer	400 H < 250 µg/L
D. Bili	0.1	0 - 0.2 mg/dL	PFA	100 CEPI <164 s; CADP <116 s
I. Bili	0.9	0.2 - 0.8 mg/dL		
Alk Phos	44	20 - 90 U/L		
ALT	20	10 - 30 U/L		
AST	9	8 - 46 U/L		
Total Protein	7.5	6 - 8 g/dL		
LDH	100	50 - 150 U/L		



Case 10 Question

- A. Switch to fondaparinux sub q and order a HIT assay
- B. Continue Heparin but start Warfarin for home treatment
- C. Switch to LMH sub q and start Warfarin for home treatment
- D. Start antiplatelet therapy using low dose aspirin

Heparin-induced thrombocytopenia (HIT)



- Due to an antibody against heparin
- Occurs in 1-3% of adult patients receiving heparin for 1 week or more. heparin binds to platelet factor 4 (PF4), forming a highly reactive antigenic complex on the surface of platelets
- An unexpected fall in platelet count occurring 4-14 days after heparin exposure
- Platelet count usually falls by 50% - Monitor CBCs
- Mean platelet count 60,000 – 100,000/uL
- Platelets become activated and induce clotting
- Associated with thrombosis - 10-30% develop arterial or venous thromboses (usually DVTs or PEs)
- Of those forming a clot, 30% will die or require amputation
- Platelet counts should be monitored while patient is on heparin therapy
- HIT Assay
- STOP all Heparin products (Flush, LMWH, Heparin) and give Direct Thrombin Inhibitor.

Non-Heparin Fondaparinux

Intrinsic Pathway –
Inside the cut
Endothelial Injury

Test = aPTT

XII to XII active
XI to XI active
IX to IX active
VIII to VIII active

Common Pathway

X to X active with V present

II Prothrombin to Thrombin

I Fibrinogen to Fibrin

fondaparinux –(Arixtra) direct Xa
blocker, good for HIT



fondaparinux

Antithrombin III



Thrombin Inhibitors

Intrinsic Pathway –
Inside the cut
Endothelial Injury

Test = aPPT

- XII to XII active
- XI to XI active
- IX to IX active
- VIII to VIII active

Common Pathway

X to X active with V present

II Prothromin to Thrombin

I Fibrinogen to Fibrin



Bivalirudin – Angiomax

Lepirudin- Refludan

Argatroban –

Antithrombin III - Thrombate II



Non Vitamin K antagonist Oral Anticoagulants - NOACs

Intrinsic Pathway –
Inside the cut
Endothelial Injury

Test = aPPT

XII to XII active
XI to XI active
IX to IX active
VIII to VIII active

Common Pathway

X to X active with V present

II Prothrombin to Thrombin

I Fibrinogen to Fibrin

May replace Coumadin with fewer side effects.

Apixaban
Rivaroxaban
Edoxaban

Dabigatran (DTI)



Case 10 Answer

- A. Switch to fondaparinux sub q and order a HIT assay
- B. Continue Heparin but start Warfarin for home treatment
- C. Switch to LMH sub q and start Warfarin for home treatment
- D. Start antiplatelet therapy using low dose aspirin

Case 10 -Heparin-induced thrombocytopenia (HIT)

<http://emedicine.medscape.com/article/1357846-overview>



Case #11

- A 20-year-old male college student is admitted for his first unprovoked DVT. He has a positive history of recurrent headaches, non vertigo dizziness and tinnitus. His lab slip is attached. What lab test would be most likely be positive?

Case 11 Labs

CBC –
 Leukocytosis 13.0 (10.8)
 Erythrocytosis RBC 7 (6)
 Thrombocytosis 500 (450)
 CMP - Normal
 UA - Negative
 Coag – Normal PFA
 Normal PT/aPTT
 Elevated D-Dimer



SPECIMEN INFORMATION:
 SPECIMEN: P121982AQW
 REQUISITION: 1973200-
 LAB REFERENCE #: H9000

PATIENT INFORMATION:
 NAME: John Smith Age: 20
 GENDER: Male
 ID: 1.071.09
 PHONE:

Case 11

ORDERING PHYSICIAN: C. Johnson
 CLIENT INFORMATION:
 EMORY PA CLINICAL OSCE
 1462 CLIFTON RD NE
 ATLANTA, GA 30322

History: Headaches, dizziness and tinnitus presents with DVT

Test Name	Result	Reference Range	Urinalysis (u/A)	
HEMATOLOGY REPORT			color	Yellow
CBC			Appearance	clear
WHITE BLOOD CELL COUNT	13.0 HIGH	3.8-10.8 THOUSAND/UL	Specific Gravity	1.024
RED BLOOD CELL COUNT	7.0 HIGH	F 4.2 - 5.4 M 4.6 - 6 million/mm3	pH	6
HEMOGLOBIN	20.0 HIGH	F 11-16 M 13.5 - 18g/oL	Protein	Negative
HEMATOCRIT	60 HIGH	F 35-45 M 40-54 %	Glucose	Negative
MCV	85	80.0-100.0 fL	Ketones	Negative
MCH	28	27.0-33.0 pg	Bilirubin	Negative
MCHC	34	32.0-36.0 g/cL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	0.2
PLATELET COUNT	500 HIGH	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	2	2	Leukocyte Esterase	Negative
RBC Morphology	Normal		Microscopic	
			WBCs/hpf	0
			RBC/hpf	0
			Epithelial Cells/hpf	0
			Bacteria	0
Metabolic Profile BMP			Coag	
Total Calcium	7.2	9 - 11 mg/dL	aPTT	30.0 23.3 - 36.6 sec
BUN	10	6 - 20 mg/dL	PT	10.1 9.1 - 13.2 Sec
Creat	0.7	0.5 - 1.0 mg/dL	PT INR	1 0.82 - 1.18
T Bili	1.0	0.3 - 1.2 mg/dL	D-Dimer	400 H < 250 µg/L
D. Bili	0.1	0 - 0.2 mg/dL	PFA	150 CEPI <164 s; CADP <116 s
I. Bili	0.9	0.2 - 0.8 mg/dL		
Alk Phos	44	20 - 90 U/L		
ALT	20	10 - 30 U/L		
AST	9	8 - 46 U/L		
Total Protein	7.5	6 - 8 g/dL		
LDH	100	50 - 150 U/L		



Case 11 Question

- A. Elevated Erythropoietin level
- B. Low Erythropoietin level
- C. Low antithrombin III
- D. Elevated Antiphospholipid (anticardiolipin) antibody



Primary - Polycythemia vera

- Sx: Pruritis HA, Dizziness, vertigo, visual disturbance, tinnitus
- PE: Rubor, BP increased, splenomegaly or hepatomegally
- Lab: HCT >55 Increased platelets and WBC count
- Low Epo and +JAK2 gene
- RX: Phlebotomy, Hydroxyurea

Emory University Physician
Assistant Program



Secondary Polycythemia

- Increase erythropoietin due to hypoxia (COPD, smokers, high altitude), tumors of kidney, ovary, liver, brain, drugs: steroids, androgen, dehydration, burns
- PE: No hepatosplenomegaly unless tumor
- Lab – Only elevated RBC, Hb, Hct

Emory University Physician
Assistant Program



Case 11 Answer

A. Elevated Erythropoietin level

B. Low Erythropoietin level

C. Low antithrombin III

D. Elevated Antiphospholipid (anticardiolipin) antibody

Case 11- Polycythemia Vera - Clue: all cell lines are increased
<http://emedicine.medscape.com/article/205114-overview#a1>



Case #12

- A 24-year-old healthy female, 8 months pregnant presents to the ED with 1 day jaundice, anorexia, weakness and nose bleeds. She does not smoke, use recreational drugs, or drink alcohol. Her lab slip is attached. What is the most likely cause these results?



Case 12 Labs

CBC - High Retic
Normocytic Anemia
Hb – 10 (11)
C –Retic 4 (2)
Thrombocytopenia 90 (140)
CMP – Tbili 5 (1.2)
Dbili 1.1 (0.2)
Ibili 4.9 (0.8)
ALT 100 (30)
AST 120 (46)
LDH 300 (150)
UA - + Ketones, 3+
Bilirubin 3+ Urobilinogen
Coag – Normal PFA
Normal PT/aPTT



SPECIMEN INFORMATION:
 SPECIMEN: P121982AQW
 REQUISITION: 1973200-
 LAB REFERENCE #: H9000

PATIENT INFORMATION:
 NAME: Jane Smith Age: 24
 GENDER: Female
 ID: 1.071.09
 PHONE:

ORDERING PHYSICIAN: C. Johnson
CLIENT INFORMATION:
 EMORY PA CLINICAL OSCE
 1462 CLIFTON RD NE
 ATLANTA, GA 30322

History: 8 months pregnant with jaundice, anorexia, weakness and nosebleeds

Test Name	Result	Reference Range	Urinalysis (u/A)	
HEMATOLOGY REPORT			color	Yellow
CBC			Appearance	clear
WHITE BLOOD CELL COUNT	9	3.8-10.8 THOUSAND/uL	Specific Gravity	1.024
RED BLOOD CELL COUNT	3.2 Low	F 4.2 - 5.4 M 4.6 - 6 million/mm3	pH	6
HEMOGLOBIN	10 Low	F 11-16 M 13.5 - 18g/dL	Protein	Negative
HEMATOCRIT	30 Low	F 35-45 M 40-54 %	Glucose	Negative
MCV	96	80.0-100.0 fL	Ketones	Positive
MCH	31.6	27.0-33.0 pg	Bilirubin	3+Positive
MCHC	34.3	32.0-36.0 g/dL	Blood	Negative
RDW	13.9	11.0-15.0 %	Urobilinogen	3+Positive
PLATELET COUNT	90 Low	140-450 Thousand /uL	Nitrite	Negative
Corrected Retic Count	4 High	2	Leukocyte Esterase	Negative
Metabolic Profile BMP			Microscopic	
Total Calcium	7.2	9 - 11 mg/dL	WBCs/hpf	0
BUN	16	6 - 20 mg/dL	RBC/hpf	0
Creat	0.8	0.5 - 1.0 mg/dL	Epithelial Cells/hpf	0
T Bilirubin	5.0 H	0.3 - 1.2 mg/dL	Bacteria	0
D. Bilirubin	1.1 H	0 - 0.2 mg/dL	Coag	
I. Bilirubin	4.9 H	0.2 - 0.8 mg/dL	aPTT	35.0 23.3 - 36.6 sec
Alk Phos	100	32 - 103 IU/L	PT	12.0 9.1 - 13.2 Sec
ALT	100 H	10 - 30 U/L	PT INR	1.0 0.82 - 1.18
AST	120 H	8 - 46 U/L	D-Dimer	200 < 250 µg/L
Total Protein	6.5	6 - 8 g/dL	PFA	90 norm CEPI <164 s; CADP <116 s
Albumin	4.0	3.4 - 4.8 g/dL		
LDH	300 H	50 - 150 U/L		
Sodium NA	140	136 - 145 mmol/L		
Potassium K	4.0	3.6 - 5.1 mmol/L		
Chloride 105	99	99 - 111 mmol/L		
Bicarb CO2	20	22 - 32 mmol/L		
Glucose	100	70 - 110 mg/dL		



Case 12 Question

- A. Hemolytic Uremic Syndrome
- B. TTP
- C. ITP
- D. HELLP syndrome



HELLP- Pregnancy

- Hemolysis (high indirect Bilirubin, LDH, high retic anemia)
- Elevated Liver Enzymes (AST, ALT)
- Low Platelets
- Severe preeclampsia (BP increased and proteinuria) increased maternal and fetal mortality
- 1 per 1000 pregnancies up to 20% with preeclampsia/eclampsia at 28 – 36 weeks gestation
- Rx Support and Deliver Baby

Thrombocytopenia

– Not HIT



Issue/ Disease	Acute ITP	Chronic ITP	TTP	HUS	DIC	HELLP
Age	Children	Adults	Adults	Children	Any	Pregnant
Cause	Immune Post viral	Immune HIV Hep C, SLE	ADAMTS- 3 and big vWF	Infections E.Coli 0157:h7	Sepsis, Burns, trauma	Pre- ecclamps ia
PT/PTT	normal	normal	normal	normal	abnorm	+/-
Fever	no	no	yes	yes	depends	+/_
Hemolysis*	no	no	yes	yes	no	yes
Organ failure	no	no	CNS > Renal	Renal > CNS	All possible	Liver
Treatment	None – IVIG, Steroids	Steroids Splenecto my	Plasma Exchange, No Plts	Support, No Plts	FFP, Cryo, platelets	Deliver (MgSO ₄)



Case 12 Answer

- A. Hemolytic Uremic Syndrome
- B. TTP
- C. ITP
- D. HELLP syndrome**

Case 12- HELLP syndrome, named for 3 features of the disease (hemolysis, elevated liver enzyme levels, and low platelet levels)

<http://emedicine.medscape.com/article/1394126-overview>

One Page Guides

- <https://anticoagulationtoolkit.org/providers>

DOAC Bleeding Management (v1 12/2016)

Prevention of Bleeding	Management of Bleeding	Reversal of Bleeding
<ul style="list-style-type: none"> Identify high-risk patients for a high risk of bleeding Identify high-risk patients for a high risk of bleeding Identify high-risk patients for a high risk of bleeding 	<ul style="list-style-type: none"> Identify high-risk patients for a high risk of bleeding Identify high-risk patients for a high risk of bleeding Identify high-risk patients for a high risk of bleeding 	<ul style="list-style-type: none"> Identify high-risk patients for a high risk of bleeding Identify high-risk patients for a high risk of bleeding Identify high-risk patients for a high risk of bleeding

Anticoagulation in Venous Thromboembolism

Prevention of VTE	Management of VTE	Reversal of VTE
<ul style="list-style-type: none"> Identify high-risk patients for a high risk of VTE Identify high-risk patients for a high risk of VTE Identify high-risk patients for a high risk of VTE 	<ul style="list-style-type: none"> Identify high-risk patients for a high risk of VTE Identify high-risk patients for a high risk of VTE Identify high-risk patients for a high risk of VTE 	<ul style="list-style-type: none"> Identify high-risk patients for a high risk of VTE Identify high-risk patients for a high risk of VTE Identify high-risk patients for a high risk of VTE

Apps: CDC anticoagulation manager






Anticoagulation Manager 17+
Centers For Disease Control and Prevention

★★★★☆ 2.7, 3 Ratings

Free

Screenshots [iPhone](#) [iPad](#)



ACC – Anticoag evaluator

AnticoagEvaluator App



Newly Updated!

We want to hear from you. Complete a [feedback survey here](#) or leave a comment on the app's iTunes or Google Play page.



Use the updated AnticoagEvaluator to make informed decisions on initiation of antithrombotic therapy for patients with atrial fibrillation (AF) who do not have moderate to severe mitral stenosis or a mechanical heart valve. App updates include expanded advice from the 2019 Focused Update to the 2014 ACC/AHA/HRS Guideline for the Management of Patients with AF.

Use the app to:

- Calculate a patient's stroke risk (CHA2DS2-VASc) and renal function (Cockcroft-Gault Equation), and review factors that may contribute to bleed risk (HAS-BLED criteria and concomitant meds)
- Consider updated stroke prevention therapy guidance based on the 2019 ACC/AHA/HRS Focused Update of the 2014 Guideline for the Management of Patients with AF
- Improve safe use of direct oral anticoagulants with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics
- Evaluate suitable therapy for a patient by reviewing:
 - Synthesized individualized risk for antithrombotic therapy options based on clinical trials (i.e.,

<https://www.acc.org/anticoagevaluator>


ACC – Anticoag App

App Screenshots

The image displays two screenshots of the ACC Anticoag App. The left screenshot shows the 'Calculate Risk' screen. At the top, there are two tabs: 'Calculate Risk' and 'Review Therapy'. Below the tabs, there are two summary boxes: 'Stroke Risk' with a value of 5 (CHA₂DS₂-VASc) and 'Renal Function' with values of 1.1 mg/dL (SCR) and 48.3 mL/min (CrCl). The main section is titled 'Calculate Risk' and includes a 'Reset All' button. Under 'Patient Information', there is a note 'Required to derive therapy options' and input fields for 'Age' (with a 'Yrs' label) and 'Sex' (with a 'Please select' dropdown). Under 'CHA₂DS₂-VASc', there is a note 'Select all that apply' and a toggle for 'CHF/LV dysfunction'. At the bottom, there is a text box: 'Make informed decisions on antithrombotic therapy initiation for patients with nonvalvular atrial fibrillation.'

The right screenshot shows the results of the calculation. At the top, it displays 'Stroke Risk' (5) and 'Renal Function' (1.1 mg/dL, 48.3 mL/min). Below this is a section titled 'Risk Factors for Major Bleed (HAS-BLED)' with a 'SCORE: 3' indicator. This section is divided into 'Non Modifiable' and 'Modifiable' factors. Under 'Non Modifiable', there are three items: 'History of Stroke/TIA/TE' (checked), 'History of Major Bleeding' (unchecked), and 'History of Labile INR' (unchecked). Under 'Modifiable', there are four items: 'Age > 65 yrs' (checked), 'Hypertension' (unchecked), 'Current *excess* of Alcohol' (unchecked), 'Abnormal Renal Function' (unchecked), 'Abnormal Liver Function' (unchecked), and 'Currently taking antiplatelet drugs or NSAIDs' (checked).

ACC – Anticoag app



Calculate Risk | **Review Therapy**

3^{CHA₂DS₂-VASc} High risk | 1.2^{SCR} mg/dL | 61.1^{CrCl} mL/min

1 Consider Therapy Guidance

Oral anticoagulant is recommended. (I,A)

If prescribing an oral anticoagulant:

- In NOAC-eligible patients*:**
 - NOACs are recommended over warfarin (I, A).
 - Renal and hepatic function should be evaluated before NOAC initiation and reevaluated at least annually (I,B). NOACs are not recommended for patients with severe hepatic dysfunction, and all NOACs have dosing defined by renal function.
 - Coverage of NOACs by patient's insurance carrier should also be considered.
- In patients initiating/taking warfarin*:**
 - INR should be determined at least weekly during initiation and monthly when anticoag (INR in range) is stable (I,A).
 - For patients unable to maintain a therapeutic INR level, NOACs are recommended (I,C).
- If on dialysis and/or with end-stage CKD (CrCl <15 mL/min):**

Review guidance from ACC/AHA/HRC's 2019 Focused Update of the 2014 Atrial Fibrillation Guideline and select from a full range of therapy options.

Calculate Risk | **Review Therapy**

3^{CHA₂DS₂-VASc} High risk | 1.2^{SCR} mg/dL | 61.1^{CrCl} mL/min

2 Select Therapy Option

Dabigatran

3 Evaluate Therapy

Standard Dose
(clinical trials) 150 mg twice daily

Stroke Risk/Benefit | Bleed Risk | Safety Info

Risk/Benefit Information*

Patient's ANNUAL risk of stroke + thromboembolism with Dabigatran 0.9%

Relative risk reduction 79%

Absolute risk reduction 3.4%

Chance of benefit per year 1 in 30

Review adjusted dosage based on prescribing information and synthesized risk for antithrombotic therapy options based on clinical trials.

Apps

- Medscape – Free in the App store
- AFP by Topic- Free EBM review articles

American Family Physician®



Clot Prevention

- Healthy diet
- Healthy weight
- Exercise
- No Smoking
- Alcohol in moderation
- Aspirin
- Statins



The **Double Coronary Bypass.**

From Vortex's menu: Beef Topped with two fried eggs, four slices of American cheese, and 5 slices of bacon, with two grilled cheese sandwiches replacing the buns.